The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

WISDOM was a 12-month, double-blind, parallel-group, active-controlled study in which all patients received triple therapy (tiotropium 18 mcg once daily, salmeterol 50 mcg twice daily and fluticasone ...

QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...

Novartis has presented data of once-daily chronic obstructive pulmonary disease (COPD) clinical trial programmes at the European Respiratory Society (ERS) Congress. Overall, Novartis presented 14 ...

Two Phase III studies demonstrated efficacy benefits of combining once-daily Onbrez Breezhaler 150 mcg with tiotropium in patients with COPD[1],[2] INTRUST 1 and 2 studies add to comprehensive data ...

Lupin has received the Food and Drug Administration’s permission for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic of Boehringer Ingelheim’s Spiriva HandiHaler. The ...

Results of two phase III studies show that once-daily Onbrez Breezhaler (indacaterol) plus tiotropium produced a significantly greater improvement in lung function than tiotropium alone in patients ...

Pulmonary function increased during sleep for patients with chronic obstructive pulmonary (COPD) receiving a triple-therapy regimen, but improvements to quality of life remain to be seen. Pulmonary ...

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 17, 2014) - Theravance, Inc. (NASDAQ: THRX) -- Respiratory Medicine has published positive results from a third lung function ...

The digital press release with multimedia content can be accessed here: Basel, May 21, 2014 - Novartis announced today new data from the QUANTIFY study, which ...